logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5418.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5418.produseast1
Antibiotic resistance, conflict and the Middle East | Collections | MSF Science Portal
Antibiotic resistance, conflict and the Middle East

Antibiotic resistance, conflict and the Middle East

Collection Content

Conference Material
|
Video

Impact of antimicrobial resistance in Middle Eastern settings

Truppa C, Ronat JB, Karah N, Shomar RA
2021-08-25 • MSF Scientific Days Asia 2021
2021-08-25 • MSF Scientific Days Asia 2021
Journal Article
|
Review

The socioeconomic burden of antibiotic resistance in conflict-affected settings and refugee hosting countries: a systematic scoping review

Kobeissi L, Menassa M, Mousally K, Repetto EC, Soboh I,  et al.
2021-04-06 • Conflict and Health
2021-04-06 • Conflict and Health
BACKGROUND
Antibiotic resistance (ABR) is a major global threat. Armed and protracted conflicts act as multipliers of infection and ABR, thus leading to increased healthcare and soci...
Journal Article
|
Commentary

Antibiotic resistance in conflict settings: lessons learned in the Middle East

Kanapathipillai R, Malou N, Hopman J, Bowman C, Yousef N,  et al.
2019-04-10 • Journal of Antimicrobial Chemotherapy
2019-04-10 • Journal of Antimicrobial Chemotherapy
Médecins Sans Frontières (MSF) has designed context-adapted antibiotic resistance (ABR) responses in countries across the Middle East. There, some health systems have been severely damag...
Journal Article
|
Research

Post-traumatic osteomyelitis in Middle East war-wounded civilians: resistance to first-line antibiotics in selected bacteria over the decade 2006-2016

Fily F, Ronat JB, Malou N, Kanapathipillai R, Seguin C,  et al.
2019-01-31 • BMC Infectious Diseases
2019-01-31 • BMC Infectious Diseases
BACKGROUND
War-wounded civilians in Middle East countries are at risk of post-traumatic osteomyelitis (PTO). We aimed to describe and compare the bacterial etiology and proportion of...
Journal Article
|
Research

Perceptions of healthcare-associated infection and antibiotic resistance among physicians treating Syrian patients with war-related injuries

Alga A, Karlow Herzog K, Alrawashdeh M, Wong S, Khankeh H,  et al.
2018-12-01 • International Journal of Environmental Research and Public Health
2018-12-01 • International Journal of Environmental Research and Public Health
Healthcare-associated infections (HAIs) constitute a major contributor to morbidity and mortality worldwide, with a greater burden on low- and middle-income countries. War-related injuri...
Journal Article
|
Letter

Antibiotic resistance in Palestine: an emerging part of a larger crisis

Kanapathipillai R, Malou N, Baldwin K, Marty P, Rodaix C,  et al.
2018-10-15 • British Medical Journal (BMJ)
2018-10-15 • British Medical Journal (BMJ)

See more collections

MSF logo
Diphtheria
No description available
Diabetes care in humanitarian settings
Diabetes care in humanitarian settings
Diabetes affect hundreds of millions of people worldwide, a large majority of them living in low- and middle-income countries. Yet finding effective strategies, tools and policies for effectively managing this chronic illness—especially amid war, displacement or exclusion from care—is a neglected area of humanitarian medicine. Here we present a cross-section of work on this front by MSF and collaborators. Several studies assess the shift towards community-based, nurse-led models of care in rural settings. Others explore obstacles to diabetes care for war refugees living in camps in Jordan or Lebanon, highlighting how health programs can adapt to their needs. The demonstration that insulin retains potency for 30 days if cooled without refrigeration is opening doors to more patient self-management, as a case study in remote South Sudan shows. At the same time, MSF and others call for regulatory and financing policies that make diabetes medications and supplies cheaper, better adapted to humanitarian settings, and far more available to patients whose lives depend on them.
Snake envenoming: a neglected crisis
Snake envenoming: a neglected crisis

Every year 2 million or more people fall victim to snakebite envenoming, mostly in poor, rural communities of Africa, Asia and Latin America. Between 83,000—138,000 of them die, while hundreds of thousands more suffer debilitating long-term complications or disabilities.


Although some antivenom medicines are highly effective when used promptly and appropriately, many snakebite victims get no treatment at all. Those who do may receive antivenoms which don’t work against the type of snake that bit them, or were not rigorously tested for safety and effectiveness.


To mark World Snakebite Awareness Day on September 19th, the Collection linked below brings together recent MSF work on this highly neglected disease. Several articles and conference presentations help fill evidence gaps on the burden of disease and its impacts or on treatment outcomes with specific antivenoms in specific regions. Others examine how to tackle the formidable challenges of availability and affordability, the absence of regulatory oversight for making, testing and registering antivenoms, and the anemic R&D pipeline for new products—all of which impede access for patients to safe, effective treatment tailored to local snake species.

View All Collections